HRSA-21-099: Community-Led Monitoring (CLM) of HIV Services in Sierra Leone
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make one award worth $100,000 in total. Applications closed on July 19, 2021.
From the official notice on Grants.gov, last changed May 20, 2021. Checked November 7, 2026.
- Total funding$100,000
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 20, 2021 |
|---|---|
| Deadline | July 19, 2021 |
| Archived by Grants.gov | September 17, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Domestic or foreign public or non-profit private entities, including schools of medicine, nursing, public health, management and public administration, and academic health centers, community based organizations, faith-based organizations, and consortia consisting of such organizations are eligible to apply.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the President’s Emergency Plan for AIDS Relief (PEPFAR) Community-Led Monitoring (CLM) of HIV Services in Sierra Leone. The purpose of this program is to use standardized data collection tools to conduct CLM of HIV services in approximately 30 PEPFAR service sites in Sierra Leone for dissemination throughout the country to promote improvements in the national HIV response. This CLM program will use client feedback collected by trained community members in order to improve performance of PEPFAR service delivery. Areas of focus include HIV prevention services, testing services, treatment services (including linkage, retention, and viral load testing), service provider perceptions, attitudes, practices, and client satisfaction with services provided. The recipient will present and analyze data in close collaboration with community representatives, healthcare providers, clients, government stakeholders, and facility managers to ensure dialogue and participation in identifying improvement opportunities, and implementing and monitoring solutions. Specifically, PEPFAR intends to utilize this program to focus on getting input from recipients of HIV services, especially key populations and underserved groups, in a routine and systematic manner that will translate into action and change. The goal of this program is to improve HIV care and services for a better client experience, and, ultimately, improve health outcomes through PEPFAR site and service monitoring. The objective of the program is to develop and conduct an assessment and reporting CLM system that reflects clients’ experience in receiving quality HIV services in Sierra Leone and support stakeholder analysis with actionable insights. Given the low overall national prevalence of HIV in Sierra Leone, the PEPFAR program focuses on key and priority Populations. At sites where PEPFAR is providing support, CLM extends to all people living with HIV (PLHIV) and for any individual seeking HIV prevention and testing services. The CLM program in Sierra Leone will give voice to those individual community members PEPFAR serves, to strengthen the quality of service provision by ensuring feedback from PLHIV is captured and used to enhance program quality.
Who has won Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief grants before
From fiscal 2021 to 2025, Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief (93.266) awarded $129 million across 16 grant awards, an average of $8.1 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Washington | Washington | 3 | $53.8 million |
| Jhpiego Corp | Maryland | 4 | $34.4 million |
| Meharry Medical College | Tennessee | 1 | $25.8 million |
| The Regents of the University of California, San Francisco | California | 2 | $7.5 million |
| The Trustees of Columbia University in the City of New York | New York | 3 | $4.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-21-099 still open?
No. It closed on July 19, 2021.
Who can apply for Community-Led Monitoring (CLM) of HIV Services in Sierra Leone?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Community-Led Monitoring (CLM) of HIV Services in Sierra Leone?
Closed July 19, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $100,000 in total for one award.
Who has won Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief grants before?
The largest recipients over five fiscal years were University of Washington, Jhpiego Corp, Meharry Medical College. The program made 16 awards worth $129 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)